• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform

    AGC Biologics Appoints Jun Takami GM of Chiba Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Alkermes, Merck Enter Clinical Trial and Supply Agreement

    Sterling Pharma Solutions Acquires ADC Biotechnology

    Moderna, Catalent Enter Long-Term Strategic Vax Pact
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success

    Enteris BioPharma: Custom Solutions – From Bench to Market

    The Benefits of Outsourcing Cold Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ

    Ascendia Pharmaceuticals Poised for Expansion

    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform

    Agilex Biolabs Acquires TetraQ for APAC Expansion Plans

    Alkermes, Merck Enter Clinical Trial and Supply Agreement
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market

    Metrics Contract Services Completes Russian Regulatory Inspection
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Almac Group

    Syngene

    Adare Pharma Solutions

    PCI Pharma Services

    Alcami
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Syngene

    Emergent BioSolutions

    Quotient Sciences

    Almac Group

    Aphena Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Clinical Trial Feasibility

    How to reduce late-stage trial risk with feasibility analysis

    Clinical Trial Feasibility
    Related CONTENT
    • Parexel Appoints Chief Patient Officer
    • Data Management in the Face of Growing Trial Complexity
    • AlzProtect & PAREXEL Biotech Enter Collaboration
    • Immuno-oncology Safety Assessment
    • Selexis, Turgut Expand Biosimilar Development Pact
    Alan Scott and Denis McMillan, PAREXEL International04.05.19
    Late-stage clinical research remains a risky and costly business despite the reasonable expectation that risks would decrease as products advance successfully through the earlier phases of development. But, in fact, about half of Phase III trials fail.

    Trials fail for a variety of reasons, including flawed science or study design, suboptimal dosing, poor study execution, slow patient enrollment, high dropout rates and, finally, a failure to demonstrate clinical or commercial value. 

    Most companies conduct at least some form of feasibility testing on their trial designs because they know that changes and miscalculations can cause delays and cost money. For example, the direct cost to implement a single protocol amendment averages approximately $500,000 in unplanned expenses and adds 61 days to project timelines. But a rudimentary glance at feasibility is not enough.

    The surest way to mitigate and even avoid many of the risks of later-stage studies is to methodically and comprehensively examine the feasibility of a study’s design before it starts.

    Once you’ve determined what’s feasible, who’s listening? 

    Feasibility analysis exists to inform clinical decision-makers about a variety of risks. But identifying and quantifying them is not enough. Risk analysis should stimulate action. And to drive action, feasibility analysis should be informed by quality data from multiple sources. There are many reasons why clinical trials fail to meet timelines, and feasibility-testing must look at all aspects of operationalizing a trial (see Table 1).


    Table 1. Key Elements of a Systematic Risk-Based Feasibility Analysis

    Accessing and interpreting the vast number of potential data sources that can aid in vetting a trial’s design is not always straightforward. Assessing the credibility of each data source is crucial and requires deep expertise. The increasing complexity of modern trial designs—which include, for example, narrow genetic eligibility criteria that require screening and involve administering technologically-advanced, expensive treatments—requires increasingly sophisticated analytic methods to determine possible impacts on a trial’s success. Adding to this difficulty, feasibility analyses are almost always conducted under tight time constraints.

    The ability to quantify and communicate risk empowers sponsors to mitigate it. Every solution discovered through feasibility analyses will be a compromise between market access, time, cost and science. Feasibility data should both motivate and reassure decision-makers. Suggesting that a study design “might be challenging” is one thing; putting a monetary value on what the challenges may cost a sponsor is a surer way to get the attention of senior management.

    The primacy of human data
    There is no one approach to feasibility analysis that will fit all trials. And the best data to gauge feasibility, as well as the best analytic tools to obtain that data, depend on the risks of the specific protocol, especially as they concern patients.

    For example, recently a major regulatory agency requested that a firm developing a drug for a serious neurologic condition conduct a placebo-controlled trial to demonstrate efficacy. The agency-mandated study design assumed, among other things, that patients had no therapeutic alternatives because none had gained formal regulatory approval. In fact, families had multiple off-label therapeutic options—some drugs approved for other conditions had shown efficacy and were being offered to patients on a routine basis—meaning that a placebo-controlled trial would have difficulty recruiting and retaining patients. It possibly also would be unethical. The firm engaged Parexel to conduct an arm’s-length analysis of the protocol’s viability. We interviewed patients and physicians, key opinion leaders, regulatory experts and bioethicists from a wide range of institutions about the trial’s design and how the treatment landscape had changed in recent years. We were able to quantify the negative impact of such a design on enrollment and retention and offer a data-driven argument that illustrated why a placebo-controlled trial was not feasible.

    How the patient population is defined also has a direct impact on how well a study can be executed in a real world setting. For instance, if the entry criteria are too tight, patients may be too hard to find. Sponsors must therefore strike a balance between enrolling: 1) a strictly controlled, homogeneous population to reduce the level of noise in the data and increase the probability of an efficacy finding; and 2) enough patients fast enough to hew to development timelines, which could necessitate broadening entry criteria.

    How many patients will make it through pre-screening, informed consent, screening and all the way to randomization? If, for every 100 patients screened, the sponsor ends up with one randomized patient, that will determine how many patients need to enter the top of the trial’s patient funnel.

    And what is the burden of patient recruitment on site resources and is this adequately compensated for in the research funding that sites receive? How do we motivate the principal investigator to pay for additional resources?

    Deeper understanding and quantification of the target patient population can reduce uncertainty. For example, a symptom monitoring assessment provides a picture of the prevalence of particular symptoms in a population—symptoms that may be crucial for patient trial eligibility. Electronic health data or prescription fulfillment records may be used to acquire a snapshot of a sample of patient’s current treatments and disease history which could play a critical part in the trial design and speed recruitment.

    Practical designs are grounded in what motivates patients and physicians
    A recruitment funnel analysis is both art and science: estimates need to be made in light of how patients, their families and physicians make their decision on whether to participate in a trial, or not.

    Several tools can be used to understand how those choices are made. At Parexel, we rely on medical, therapeutic area and operational experts within our own organization, and we seek advice from external experts, opinion leaders, and experienced principal investigators and their staff within our global alliance network of 350 sites.

    Engaging with investigators, patients and study site nurses who represent a critical, and often untapped reservoir of practical information and expertise provides invaluable insight. Sponsors can and should modify their protocols to address findings from surveys of these communities. In some cases, the design of a protocol may remain unchanged, but the geographic footprint of the trial can be improved. 

    For example, a recent Alzheimer’s disease study required a lumbar puncture (LP) procedure to obtain a cerebral spinal fluid sample (CSF). When a trial requires an invasive procedure of this kind it’s important to have deep knowledge of standards of care and cultural idiosyncrasies. Different countries have different levels of acceptance for certain interventions. In some European countries, LPs are widely accepted and routine; in other countries, they are rare and unfamiliar. If a study includes a non-negotiable burden—in this case, CSF sampling was needed to measure a biomarker hypothesized to be an indicator of disease progression—by understanding cultural standards, sponsors can choose sites in geographies that convey the best chance of recruitment success.

    To gain an appreciation of the patient (and family/caregiver) perspective, Parexel routinely conducts a patient burden analysis of study designs, which involves asking questions such as:
    • What are the demographics of the patients in the study and will it impact their habits? Are they elderly and therefore may have difficulty leaving home? Young adults who can travel easily? Or, small children who must be supervised by parents?
    • What is life like with this disease? Do patients have frequent medical appointments and/or hospitalizations, similar to trial site visits and assessments, or very few medical interventions, making trial-related testing and procedures more out of the ordinary?
    • What will it mean to undergo this procedure/intervention/assessment visit every week for 12 weeks when the patient and his or her family may be struggling with a frightening or discouraging disease diagnosis?
    • How far away from sites do most patients live, and what kind of transportation obstacles might they confront?
    Recently, a sponsor asked Parexel to analyze a pediatric trial that required three consecutive days of in-clinic monitoring as part of the protocol. Worried about that burden, we surveyed the families of patients with the condition for insight into how they viewed the protocol. We were surprised to find families did not find three days of on-site monitoring a burden as the untreated side effects of the condition regularly landed them in hospital settings with their children for prolonged periods. Rather, their biggest worry was about childcare options for their other, non-affected children. This insight allowed the trial’s sponsor to provide solutions that targeted the actual rather than the assumed problem; in this case, to help families arrange childcare.

    Knowing what you don’t know is valuable in managing risk
    Done correctly, analytical pressure-testing of a trial’s protocol enables sponsors to identify and eliminate unrealistic or impractical elements of the design, thereby reducing the risk of waste, missing development deadlines or outright failure. Even identifying uncertainties is worthwhile before a trial starts, giving sponsors insight as to where problems may arise and time to develop mitigation strategies.

    Ultimately, feasibility testing should drive clinical decision-makers to put contingency plans in place that would not exist otherwise. And that will increase a late-stage trial’s chance of success. 
    Related Searches
    • study
    • Clinical Trial
    • Development
    • Testing
    Suggested For You
    Parexel Appoints Chief Patient Officer Parexel Appoints Chief Patient Officer
    Data Management in the Face of Growing Trial Complexity Data Management in the Face of Growing Trial Complexity
    AlzProtect & PAREXEL Biotech Enter Collaboration AlzProtect & PAREXEL Biotech Enter Collaboration
    Immuno-oncology Safety Assessment Immuno-oncology Safety Assessment
    Selexis, Turgut Expand Biosimilar Development Pact Selexis, Turgut Expand Biosimilar Development Pact
    PAREXEL Adds Oncology Expertise  PAREXEL Adds Oncology Expertise
    Former FDA Senior Executives Join PAREXEL Former FDA Senior Executives Join PAREXEL
    Leveraging AI to Advance Discovery, Development and Delivery Leveraging AI to Advance Discovery, Development and Delivery
    Taiho and Cullinan Enter Cancer Collaboration Taiho and Cullinan Enter Cancer Collaboration
    Cytel Appoints CEO Cytel Appoints CEO
    Managing Outsourced Clinical Trials Managing Outsourced Clinical Trials
    PAREXEL Launches Biotech Division PAREXEL Launches Biotech Division
    Chi-Med and Lilly Amend 2013 Agreement Chi-Med and Lilly Amend 2013 Agreement
    AMAG Acquires Perosphere AMAG Acquires Perosphere
    PAREXEL, Lilly to Develop China’s Clinical Research Workforce PAREXEL, Lilly to Develop China’s Clinical Research Workforce

    Related Features

    • Clinical Trials | Information Technology | R&D
      Decentralized Trials Fuel AI Revolution in Clinical Research

      Decentralized Trials Fuel AI Revolution in Clinical Research

      The life sciences industry is giving clinical a full makeover, dramatically improving how new therapeutics are developed.
      Nick Moss, Vice President of Analytics and Machine Learning, Medable 11.17.20

    • Clinical Trials | Information Technology
      The Role of Electronic Monitoring in Maintaining Medication Adherence

      The Role of Electronic Monitoring in Maintaining Medication Adherence

      Digital solutions offer hope to get patients to take their medications properly.
      Bernard Vrijens, Scientific Lead, AARDEX Group 10.14.20

    • Clinical Trials
      Gene Therapy Trials

      Gene Therapy Trials

      Applications and the limitations of real-world data.
      Karen Ooms, Executive Vice President and Head of Statistics, Quanticate 09.16.19


    • Clinical Trials | Information Technology
      The New Horizon: Metaprise Analytics in Life Sciences

      The New Horizon: Metaprise Analytics in Life Sciences

      Going beyond enterprise analytics to metaprise analytics—patient-centric systems that create a data driven trial team.
      Michelle Longmire, MD, CEO and Founder, Medable 05.07.19

    • Clinical Trial Materials | Clinical Trials | Supply Chain
      Optimizing Clinical Supply Management

      Optimizing Clinical Supply Management

      IRT system design strategies to help life science companies cut drug wastage across clinical programs.
      Bart Nicholson, Director of Customer Success for IRT, CRF Bracket 04.05.19

    • Clinical Trials | R&D
      Improving Pharma R&D Efficiency: The need to transform clinical trials

      Improving Pharma R&D Efficiency: The need to transform clinical trials

      Cost pressures on drug development are driving the search for savings and efficiencies—but efforts need to be integrated if t
      ICON plc 10.10.18


    • Clinical Trials
      Tracking Health

      Tracking Health

      Exploring the impact of wearable health monitoring tools on CROs
      Nigel Walker 05.09.17

    • Clinical Trials | Drug Development | Preclinical Outsourcing | R&D
      CROs and Today’s  R&D Landscape

      CROs and Today’s R&D Landscape

      John Lewis of ACRO discusses opportunities, challenges, and the future CRO
      Kristin Brooks, Associate Editor, Contract Pharma 11.09.16

    • APIs | Clinical Trial Materials | Clinical Trials | Drug Development | Formulation Development
      Choosing Oral Formulations for First-in-man Clinical Trials

      Choosing Oral Formulations for First-in-man Clinical Trials

      Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems
      Jon Sutch, Senior Manager of Formulation Development, Patheon 10.11.16


    • Analytical Services | Bioassay Development | Clinical Trials | Preclinical Outsourcing | R&D
      Robust Assay Designs

      Robust Assay Designs

      Easing the transition from preclinical to clinical research
      Tim Wright, Editor, Contract Pharma 10.11.16

    • APIs | Clinical Trial Materials | Clinical Trials | Drug Development
      7 Steps Virtual Pharma Companies Can Take to Improve Clinical Study Success

      7 Steps Virtual Pharma Companies Can Take to Improve Clinical Study Success

      Virtual pharmaceutical companies face special challenges
      Joe Cobb, Anshul Gupte, Metrics Contract Services 10.11.16

    • Clinical Trials | Logistics | Serialization | Supply Chain
      Healthcare Companies Tackle Supply Chain Issues

      Healthcare Companies Tackle Supply Chain Issues

      UPS study shows logistics gains in some areas, challenges in others
      Jan Denecker, UPS Europe 06.02.16


    • APIs | Chemistry | Cleaning Validation | Clinical Trials | Toxicology | Validation
      Limiting APIs in Manufacturing Effluent

      Limiting APIs in Manufacturing Effluent

      An approach for setting limits on pharmaceuticals discharged in manufacturing effluent
      Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc. 06.02.16

    • Clinical Trial Materials | Clinical Trials | Drug Development
      Who’s the Right Service Provider for You?

      Who’s the Right Service Provider for You?

      Factors to consider when choosing between using one integrated CDMO or a series of smaller functional service providers
      Raymond Peck, VxP Pharma Services 06.02.16

    • Clinical Trials | Drug Development | Fill/Finish | Parenterals | Supply Chain | Vials
      Biotech Boom Fuels Parenteral Market

      Biotech Boom Fuels Parenteral Market

      Assessing the trends driving parenteral manufacturing
      Colin MacKay, Symbiosis Pharmaceutical Services 06.02.16

    Trending
    • Sterling Pharma Solutions Acquires ADC Biotechnology
    • Ascendia Pharmaceuticals Poised For Expansion
    • Sanofi To Build New $700M Flu Vaccine Facility In Canada
    • Frontage Expands Capabilities At Its Clinical Site In Secaucus, NJ
    • Merck KGaA Selects PRA’s Remote Patient Monitoring Platform
    Breaking News
    • Bora Pharmaceuticals Adds Roller Compaction Capabilities
    • Ascendia Pharmaceuticals Poised for Expansion
    • Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ
    • Merck KGaA Selects PRA’s Remote Patient Monitoring Platform
    • AGC Biologics Appoints Jun Takami GM of Chiba Site
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Kyowa Hakko Launches Heat-Treated Probiotic Strain for Eye Health
    CGA-7 Green Coffee Extract by Vidya Herbs Achieves Self-Affirmed GRAS Status
    Nutritional Complex Evidenced to Reduce Preterm Birth
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies to Sponsor and Exhibit at the North American Pultrusion Conference 2021
    Barentz Expands Canadian CASE Team
    Shepherd Color Company Opens Sales Office in China
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    CMS Establishes New Payment for Pelvalon’s Eclipse System
    Varian, Google Cloud Partner to Bring Convenience to Cancer Therapy
    Resonetics Leases New Manufacturing Space in Costa Rica
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ
    Ascendia Pharmaceuticals Poised for Expansion
    Bora Pharmaceuticals Adds Roller Compaction Capabilities
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Revlon Unveils New Fragrances Featuring Megan Thee Stallion & Sofia Carson
    Henkel Management Board Welcomes Wolfgang König
    Mielle Organics Gets a Major Investment
    Happi

    Latest Breaking News From Happi

    Nature’s Beauty Debuts Vegan Natural Body Care at Walgreens
    Estée Lauder Expands Beautiful Fragrance Collection
    The Honest Company Files for IPO
    Ink World

    Latest Breaking News From Ink World

    SE-DA Invests in Kornit Presto S
    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    Iron Oxide Pigments Market to Register 4.7% CAGR from 2021 to 2028: GVR
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Dantex elevates Joseph Sanchez to digital business development manager
    Mactac's Kevin Clunie joins TLMI panel
    MacDermid announces two new global sales roles
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Precision Textiles Offers Biodegradable Medical Fabric
    Northshore Launches Megamax Briefs in New Colors
    Essity Acquires Distribution Rights to Sorbact in Australia and New Zealand
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    New Biosealant Could Stabilize Cartilage, Boost Healing After Injury
    Google Executive Joins SeaSpine's Board of Directors
    HSS and LimaCorporate Open Provider-Based 3D Design and Printing Facility
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Tive Multi-sensor Tracker Solo 5G Relies on Sensirion SHT33
    VTT in 2020: Successful Year Despite Globally Challenging Times
    Lux Research: 3D Printing Market to Reach $51 Billion in 2030

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login